Ledipasvir/sofosbuvir fixed‐dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus

201627 citationsJournal Article

Authors

Wan‐Long Chuang · Kaohsiung Medical University

Rong‐Nan Chien · Keelung Chang Gung Memorial Hospital

Cheng‐Yuan Peng · China Medical University

Ting‐Tsung Chang · National Cheng Kung University Hospital

Gin‐Ho Lo · E-Da Hospital

I‐Shyan Sheen · Chang Gung Memorial Hospital

Horng‐Yuan Wang

Abstract

Data from this phase 3b study suggest that 12 weeks of once-daily treatment with the interferon-free, ribavirin-free regimen ledipasvir/sofosbuvir is effective and well-tolerated in Taiwanese patients with chronic genotype 1 HCV infection, irrespective of treatment history.

Topics & Keywords

Hepatitis C virus research Liver Disease Diagnosis and Treatment HIV/AIDS drug development and treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Gastroenterology and Hepatology

Volume 31, Issue 7, pp. 1323-1329

DOI: 10.1111/jgh.13305

Field-Weighted Citation Impact: 2.93